Kozak Anna, Talar-Wojnarowska Renata, Kaczka Aleksandra, Borkowska Anna, Czupryniak Leszek, Małecka-Panas Ewa, Gąsiorowska Anita
Anna Kozak, Renata Talar-Wojnarowska, Aleksandra Kaczka, Ewa Małecka-Panas, Anita Gąsiorowska, Department of Digestive Tract Diseases, Medical University of Lodz, 90-153 Lodz, Poland.
World J Gastrointest Oncol. 2016 Aug 15;8(8):635-41. doi: 10.4251/wjgo.v8.i8.635.
AIM: To estimate the levels of serum cytokines in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) patients in order to evaluate their usefulness as possible biomarkers. METHODS: The study included 167 Caucasian patients: 74 with PDAC (28 men and 42 women, aged 30-88 years), 78 with CP (50 men and 21 women, aged 20-79 years) and 15 age-matched healthy controls hospitalized in the Department of Digestive Tract Diseases, Medical University of Lodz, Poland between 2006 and 2013. Serum MCP-1, transforming growth factor (TGF)-β1, HA and s-Fr were measured in patients with CP (n = 78), PDAC (n = 74) and healthy controls (n = 15) using ELISA (Corgenix United Kingdom Ltd R and D Systems). The severity of CP was assessed according to the Cambridge classification. RESULTS: Both patients with CP and PDAC had a significantly higher mean TGF-β1 serum level (1066 ± 582 and 888 ± 356 vs 264 ± 93, P < 0.0001), mean s-Fr (2.42 ± 1.385 and 2.41 ± 1.275 vs 0.6 ± 0.370, P < 0.0001) and mean HA (199 ± 254 and 270 ± 358 vs 40 ± 26, P < 0.0001) compared to controls. There was no difference in mean MCP-1 between all the groups. There were no significant differences in any cytokine levels between the PC and PDAC groups. No significant differences between serum cytokines depending on age, gender or smoking status were found in CP patients. Mean s-Fr concentration was significantly higher in CP, lasting longer than 5 years compared to those with a shorter disease clinical course (2.639 ± 1.125 vs 1.870 ± 0.970, P < 0.03). There was no correlation between tumor size, localization or TNM classification and serum TGF-β1, MCP-1, s-Fr and HA levels in patients with PDAC. No significant differences between cytokines depending on diabetes presence in CP were found. Nevertheless, mean serum TGF-β1 concentration in PDAC patients was higher in those with diabetes compared to the remaining group (986 vs 839, P = 0.043). CONCLUSION: Serum TGF-β1, s-Fr and HA may be considered additional diagnostic markers of CP and PDAC. TGF-β1 may be useful to predict endocrine insufficiency in PDAC.
目的：评估慢性胰腺炎（CP）和胰腺导管腺癌（PDAC）患者血清细胞因子水平，以评价其作为潜在生物标志物的效用。 方法：该研究纳入了167名白种人患者：74例PDAC患者（28例男性和42例女性，年龄30 - 88岁），78例CP患者（50例男性和21例女性，年龄20 - 79岁），以及15名年龄匹配的健康对照者，这些患者于2006年至2013年期间在波兰罗兹医科大学消化道疾病科住院。采用酶联免疫吸附测定法（ELISA，英国Corgenix公司研发系统）检测CP患者（n = 78）、PDAC患者（n = 74）和健康对照者（n = 15）血清中的单核细胞趋化蛋白-1（MCP-1）、转化生长因子（TGF）-β1、透明质酸（HA）和可溶性纤维连接蛋白（s-Fr）。根据剑桥分类法评估CP的严重程度。 结果：与对照组相比，CP患者和PDAC患者的血清TGF-β1平均水平（分别为1066±582和888±356，对照组为264±93，P < 0.0001）、s-Fr平均水平（分别为2.42±1.385和2.41±1.275，对照组为0.6±0.370，P < 0.0001）和HA平均水平（分别为199±254和270±358，对照组为40±26，P < 0.0001）均显著更高。所有组间MCP-1的平均水平无差异。PC组和PDAC组之间任何细胞因子水平均无显著差异。在CP患者中，未发现血清细胞因子水平在年龄、性别或吸烟状况方面存在显著差异。病程超过5年的CP患者的平均s-Fr浓度显著高于病程较短者（2.639±1.125 vs 1.870±0.970，P < 0.03）。在PDAC患者中，肿瘤大小、位置或TNM分类与血清TGF-β1、MCP-1、s-Fr和HA水平之间无相关性。在CP患者中，未发现细胞因子水平在是否患有糖尿病方面存在显著差异。然而，PDAC患者中患有糖尿病者的血清TGF-β1平均浓度高于其余患者（986 vs 839，P = 0.043）。 结论：血清TGF-β1、s-Fr和HA可被视为CP和PDAC的额外诊断标志物。TGF-β1可能有助于预测PDAC中的内分泌功能不全。
World J Gastrointest Oncol. 2016-8-15
World J Gastroenterol. 2008-11-14
Prz Gastroenterol. 2014
Clin Endosc. 2014-5
Br J Cancer. 2013-10-1
Acta Histochem Cytochem. 2013-3-5
BMC Gastroenterol. 2013-1-16
Zotero 插件